



Biomarkers for Neurodegenerative Disorders: From Bench to Bedside

Guest Editor:

Dr. George P. Paraskevas

2nd Department of Neurology,
School of Medicine, National and
Kapodistrian University of
Athens, Athens, Greece

Deadline for manuscript
submissions:

31 October 2024

Message from the Guest Editor

Our knowledge on neurodegenerative disorders is rapidly expanding. Molecular, neuropsychological and imaging markers are valuable tools to understand the various mechanisms underlying these disorders. In addition, such biomarkers may be of clinical value, and some of them have been incorporated in diagnostic criteria and guidelines for neurodegenerative disorders. This Special Issue provides insights into the use of biomarkers in neurodegenerative disorders, including (but not limited to) Alzheimer's disease, frontotemporal dementias, Lewy body dementia, Parkinson's disease, atypical parkinsonian disorders and amyotrophic lateral sclerosis. Among others, fluid biomarkers (cerebrospinal fluid or blood), structural imaging biomarkers (atrophy), positron emission tomography (PET) biomarkers (amyloid- and/or tau-PET and others) and genetic biomarkers are especially important. Papers on biomarkers related to basic mechanisms are welcome, but the main interest is on clinically meaningful biomarkers, their help in the diagnosis of patients with cognitive and movement disorders, and in selecting patients for newer or emerging treatments.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)